Product Description
Mechanisms of Action: CA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Germany | India | Ireland | Italy | Korea | New Zealand | Pakistan | Taiwan | United Kingdom | United States
Approved Indications: Paralysis | Hypokalemic Periodic Paralysis | Paralysis, Hyperkalemic Periodic
Known Adverse Events: Confusion | Dysgeusia | Paresthesia
Company: University of Rochester
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hypokalemic Periodic Paralysis|Myotonia Congenita|Paralysis, Hyperkalemic Periodic|Myotonic Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2008-002306-19 | P3 |
Completed |
Paralysis, Hyperkalemic Periodic|Hypokalemic Periodic Paralysis |
2013-05-05 |
|
HYP-HOP | P3 |
Completed |
Paralysis, Hyperkalemic Periodic|Hypokalemic Periodic Paralysis |
2013-04-01 |
|
OSU-92H0173 | P3 |
Completed |
Hypokalemic Periodic Paralysis|Myotonia Congenita|Paralysis, Hyperkalemic Periodic|Myotonic Disorders |
None |